Literature DB >> 21997610

Seattle Genetics rare cancer drug sails through accelerated approval.

Laura DeFrancesco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21997610     DOI： 10.1038/nbt1011-851

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

Review 1.  Accelerated approval of oncology products: the food and drug administration experience.

Authors:  John R Johnson; Yang-Min Ning; Ann Farrell; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

2.  Accelerated approval of oncology drugs: can we do better?

Authors:  Susan S Ellenberg
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

3.  FDA panel votes to pull Avastin in breast cancer, again.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2011-08-05       Impact factor: 54.908

4.  Pushing the envelope.

Authors: 
Journal:  Nat Biotechnol       Date:  2011-08-05       Impact factor: 54.908

5.  Can cancer clinical trials be fixed?

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908
  5 in total
  2 in total

1.  Fresh from the biotech pipeline--2011 [corrected].

Authors:  Jim Kling
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

Review 2.  State of the art in the treatment of Hodgkin lymphoma.

Authors:  Peter Borchmann; Dennis A Eichenauer; Andreas Engert
Journal:  Nat Rev Clin Oncol       Date:  2012-06-12       Impact factor: 66.675
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.